Total Funding
45
13
Total FundingSeries A raised
Growth Score
-1 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
416767
Cytodel offers an early biopharma with technology platform that delivers therapeutic Abs to the inside of neurons.
Catherine Banat: Member
About the Company
CytoDel is a biopharmaceutical company that uses the tools of 21st-century molecular biology to produce recombinant derivatives of botulinum neurotoxin (BoNT) customized to specific applications.
The technology allows CytoDel to manipulate the BoNT molecule, for next-generation BoNT products and into a drug delivery vehicle that can deliver
therapeutic molecules to the inside of neurons.
Biodefense is our top priority but CytoDel is developing programs to advance the treatment of nervous system disorders, chronic pain, and neurodegenerative diseases.
